<DOC>
	<DOCNO>NCT01903005</DOCNO>
	<brief_summary>The purpose study assess safety , efficacy , treatment retention follow extend treatment OX219 , higher-bioavailability buprenorphine/naloxone ( BNX ) sublingual tablet formulation opioid-dependent patient complete 1 2 primary efficacy safety study OX219 .</brief_summary>
	<brief_title>Multi-Center , Open-Label , 24-Week Study OX219 Safety Efficacy Maintenance Treatment Opioid Dependence</brief_title>
	<detailed_description>This multicenter , open-label , uncontrolled , single-arm , 24-week , extension study ass safety , efficacy , treatment retention maintenance treatment . Eligible patient complete 1 2 primary efficacy safety study higher-bioavailability BNX sublingual tablet formulation ( primary study OX219-006 [ NCT01908842 ] OX219-007 [ NCT01848054 ] ) . The total duration study treatment 24 week .</detailed_description>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>Inclusion criterion Signed informed consent form . Completion 1 2 primary efficacy safety study BNX sublingual tablet ( OX219006 OX219007 ) . Female patient child bear potential use reliable method contraception ( hormonal , condom spermicide , intrauterine device ) previous OX219006 OX219007 study continue use OX219008 study . Females childbearing potential either surgically sterile ( hysterectomy , bilateral oophorectomy , bilateral salpingectomy , tubal ligation ) , postmenopausal , define least 50 year age absence menses least 2 year , also eligible . Exclusion criterion Females pregnant ( positive pregnancy test result ) lactating , plan become pregnant study . Participants unwilling unable comply requirement protocol ( eg , pending incarceration ) situation condition , opinion investigator , may interfere participation study . Participants participate clinical study medication ( ) deliver used investigational drug device within last 30 day . Participants know allergy sensitivity intolerance buprenorphine , naloxone , related drug , history drug hypersensitivity intolerance , opinion investigator , would compromise safety subject study . Participant contraindicate serious medical condition . Participants suicidal risk determine follow : history suicidal ideation â‰¤ 3 month prior baseline score 4 ( intent act ) 5 ( specify plan intent ) Columbia Suicide Severity Risk Scale ( CSSRS ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Opioid , Dependence , agonist , Buprenorphine , Naloxone</keyword>
</DOC>